Pharmaceuticals & Life Sciences · Medical Affairs & Medical Science Liaisons
KOL Engagement & Scientific Exchange
Trajectories describe the observable direction of human effort — not a prediction about specific roles, headcount, or individual careers.
What You Do Today
Identify and build relationships with key opinion leaders (KOLs) — academic researchers, clinical investigators, guideline authors, and formulary decision-makers. Conduct scientific exchange on disease state knowledge, clinical data, and investigator-initiated research opportunities.
AI Technologies
Roles Involved
How It Works
AI maps the KOL landscape by analyzing publication records, clinical trial participation, conference presentations, guideline authorship, and social media influence. Engagement analytics track interaction history and identify optimal engagement timing and topics for each KOL.
What Changes
KOL identification shifts from manual peer nomination to data-driven mapping that discovers rising experts and cross-therapeutic-area influencers. Engagement planning becomes more strategic with AI-powered interaction tracking.
What Stays the Same
Building genuine scientific relationships with KOLs, conducting substantive scientific exchange that respects compliance boundaries, and earning the trust of researchers through scientific credibility are fundamentally human skills.
Evidence & Sources
- •Medical Affairs Professional Society benchmarks
- •MSL Society KOL engagement surveys
Sources listed are directional references, not formal citations. Verify against primary sources before using in business cases or presentations.
Last reviewed: March 2026
What To Do Next
This section won't tell you what your numbers should be. It will show you how to find them yourself. Every instruction below produces a real, verifiable result in your organization. No benchmarks, no projections — just the steps to build your own evidence.
Establish Your Baseline
Know where you are before you move
Before adopting AI tools for kol engagement & scientific exchange, document your current state in medical affairs & medical science liaisons.
Without a baseline, you can't tell whether AI actually improved kol engagement & scientific exchange or just changed who does it.
Define Your Measures
What to track and how to calculate it
patient outcomes
How to calculate
Measure patient outcomes for kol engagement & scientific exchange before and after AI adoption. Pull from your EHR system.
Why it matters
This is the most direct indicator of whether AI is adding value to medical affairs & medical science liaisons.
clinical documentation quality
How to calculate
Track clinical documentation quality using the same methodology you use today. Don't change how you measure just because you changed how you work.
Why it matters
Speed without quality is just faster mistakes. Measure both together.
Start These Conversations
Who to talk to and what to ask
CMO or VP Clinical Operations
“What's our plan for AI in medical affairs & medical science liaisons? Are we piloting, planning, or waiting?”
This tells you whether to experiment quietly or push for formal investment in kol engagement & scientific exchange.
your EHR system administrator or vendor
“What AI capabilities exist in our current EHR system that we're not using? Most platforms are adding AI features faster than teams adopt them.”
The cheapest AI adoption is the features already included in your existing license.
a practitioner in medical affairs & medical science liaisons at another organization
“Have you deployed AI for kol engagement & scientific exchange? What worked, what didn't, and what would you do differently?”
Peer experience is more useful than vendor demos. Find someone who has actually done this.
Check Your Prerequisites
Confirm readiness before you invest
Check items as you confirm them.